X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Daiichi Sankyo Launches NaruveinⓇ Injection for Cancer Pain Treatment in Japan

Content Team by Content Team
24th May 2018
in Drug Development, Featured, Press Statements

Daiichi Sankyo Company, Limited announced that it has launched in Japan an injection for cancer pain treatment: NaruveinⓇ Injection 2 mg • 20 mg.

Hydromorphone hydrochloride is an opium-based narcotic analgesic that has been sold for more than 80 years outside Japan and positioned as the standard drug for pain management in the World Health Organization (WHO) guidelines for cancer pain treatment.

Joining the currently marketed extended-release formulation, NarususⓇ Tablets, and immediate-release formulation, NarurapidⓇ Tablets, the injection formulation, NaruveinⓇ Injection, is a new addition to Daiichi Sankyo’s analgesic line-up to help meet the diverse needs of patients and health care professionals in Japan.

Hydromorphone hydrochloride is one of the agents publicly offered for development by the Review Committee on Unapproved Drugs and Indications with High Medical Needs*. Daiichi Sankyo decided to develop the drug in 2012, and received a grant from the Pharmaceutical Development Support Center for its development.

Product Outline

Daiichi Sankyo is committed to making unapproved and off-label drugs with high medical needs available to the patients who are waiting for them.

* A committee held by Japan’s Ministry of Health, Labour and Welfare that aims to promote the development of drugs and indications not yet approved in Japan, but currently available in Europe and the U.S.

About Daiichi Sankyo Opioid Analgesics
Daiichi Sankyo contributes to the total care for the life of patients with cancer by providing opioid analgesics. A diverse line-up of narcotic analgesic drugs supports patients living with cancer by relieving pain and improving QOL. In Japan, in addition to the hydromorphone chloride preparations, NarususⓇ Tablets (extended-release formulation), NarurapidⓇ Tablets (immediate-release formulation), and NaruveinⓇ Injection (injection formulation), Daiichi Sankyo also markets the oxycodone hydrochloride preparations, Oxycodone Extended Release Tablets Daiichi Sankyo

Previous Post

Herbalife Nutrition Announces the Adjusted Price Range of Its Dutch Auction Tender Offer for Common Shares Following Stock-Split

Next Post

OLUMIANT® (baricitinib) 2-mg Tablets gets FDA approval to treat adult patients with moderately to severely active Rheumatoid Arthritis

Related Posts

ACHEMA 2022 addresses the industry's key issues digitalisation and sustainability
Manufacturing

ACHEMA 2022 addresses the industry’s key issues digitalisation and sustainability

14th June 2022
Time Congress Acts As Drug Launch Prices Go Up 20% Annually
Featured

Time Congress Acts As Drug Launch Prices Go Up 20% Annually

11th June 2022
FDA Approves Eli Lilly Precision Oncology Treatment for Certain Lung and Thyroid Cancers
Featured

History Created- Every Patient In Drug Trial Is Cancer-Free

8th June 2022
Promising Findings of Drug Mix Targeting Cancers Death Star
Featured

Promising Findings of Drug Mix Targeting Cancers Death Star

7th June 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
Featured

ICMR Issues Standards For Drones To Deliver Medical Supplies

7th June 2022
development of new antibiotics
Drug Development

EMA guidance supports development of new antibiotics

30th May 2022
Next Post
OLUMIANT® (baricitinib) 2-mg Tablets gets FDA approval to treat adult patients with moderately to severely active Rheumatoid Arthritis

OLUMIANT® (baricitinib) 2-mg Tablets gets FDA approval to treat adult patients with moderately to severely active Rheumatoid Arthritis

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In